May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Healthy, but Still Hurting: Challenges of Cancer Survivorship
Dr Charlie Fazio on Balancing Different Delivery and Payment Models